静脉注射尼可地尔治疗急性失代偿性心力衰竭患者:一项随机对照试验的荟萃分析。

IF 1 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Yan Zhu, Shanshan Xie
{"title":"静脉注射尼可地尔治疗急性失代偿性心力衰竭患者:一项随机对照试验的荟萃分析。","authors":"Yan Zhu, Shanshan Xie","doi":"10.1080/14017431.2023.2220556","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Pilot studies have suggested the potential benefits of intravenous nicorandil for patients with acute decompensated heart failure (ADHF). However, clinical evidence remains limited. The aim of the study was to summarize the efficacy and safety of intravenous nicorandil for the treatment of ADHF.</p><p><strong>Design: </strong>A systematic review and meta-analysis was performed. The search for relevant randomised controlled trials (RCTs) was conducted in PubMed, Embase, Cochrane's Library, Wanfang, and CNKI databases. A random-effects model was employed to combine the results.</p><p><strong>Results: </strong>Eight RCTs contributed to the meta-analysis. Pooled results showed that acute treatment with intravenous nicorandil could significantly improve the symptom of dyspnea at 24 h after treatment, as evidenced by the five-point Likert scale for dyspnea after treatment (mean difference [MD]: -0.26, 95% confidence interval [CI]: -0.40 to -0.13, <i>p</i> < 0.001). Furthermore, nicorandil significantly reduced serum B natriuretic peptide (MD: -30.03 ng/dl, 95% CI: -47.00 to -13.06, <i>p</i> < 0.001), and N-terminal proBNP (MD: -138.69, 95% CI: -248.06 to -29.31, <i>p</i> = 0.01). In addition, nicorandil significantly improved ultrasonic parameters including left ventricular ejection fraction and E/e' at discharge. Moreover, during the follow-up duration of up to 90 days, intravenous nicorandil significantly reduced the incidence of major adverse cardiovascular events (risk ratio [RR]: 0.55, 95% CI: 0.32 to 0.93, <i>p</i> = 0.03). The incidence of treatment-related adverse events was not significantly different between nicorandil and controls (RR: 1.22, 95% CI: 0.69 to 2.15, <i>p</i> = 0.49).</p><p><strong>Conclusions: </strong>Results of this study suggest that intravenous nicorandil may be an effective and safe treatment for patients with ADHF.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"57 1","pages":"2220556"},"PeriodicalIF":1.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intravenous nicorandil for patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials.\",\"authors\":\"Yan Zhu, Shanshan Xie\",\"doi\":\"10.1080/14017431.2023.2220556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Pilot studies have suggested the potential benefits of intravenous nicorandil for patients with acute decompensated heart failure (ADHF). However, clinical evidence remains limited. The aim of the study was to summarize the efficacy and safety of intravenous nicorandil for the treatment of ADHF.</p><p><strong>Design: </strong>A systematic review and meta-analysis was performed. The search for relevant randomised controlled trials (RCTs) was conducted in PubMed, Embase, Cochrane's Library, Wanfang, and CNKI databases. A random-effects model was employed to combine the results.</p><p><strong>Results: </strong>Eight RCTs contributed to the meta-analysis. Pooled results showed that acute treatment with intravenous nicorandil could significantly improve the symptom of dyspnea at 24 h after treatment, as evidenced by the five-point Likert scale for dyspnea after treatment (mean difference [MD]: -0.26, 95% confidence interval [CI]: -0.40 to -0.13, <i>p</i> < 0.001). Furthermore, nicorandil significantly reduced serum B natriuretic peptide (MD: -30.03 ng/dl, 95% CI: -47.00 to -13.06, <i>p</i> < 0.001), and N-terminal proBNP (MD: -138.69, 95% CI: -248.06 to -29.31, <i>p</i> = 0.01). In addition, nicorandil significantly improved ultrasonic parameters including left ventricular ejection fraction and E/e' at discharge. Moreover, during the follow-up duration of up to 90 days, intravenous nicorandil significantly reduced the incidence of major adverse cardiovascular events (risk ratio [RR]: 0.55, 95% CI: 0.32 to 0.93, <i>p</i> = 0.03). The incidence of treatment-related adverse events was not significantly different between nicorandil and controls (RR: 1.22, 95% CI: 0.69 to 2.15, <i>p</i> = 0.49).</p><p><strong>Conclusions: </strong>Results of this study suggest that intravenous nicorandil may be an effective and safe treatment for patients with ADHF.</p>\",\"PeriodicalId\":21383,\"journal\":{\"name\":\"Scandinavian Cardiovascular Journal\",\"volume\":\"57 1\",\"pages\":\"2220556\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Cardiovascular Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14017431.2023.2220556\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Cardiovascular Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14017431.2023.2220556","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:初步研究表明静脉注射尼可地尔对急性失代偿性心力衰竭(ADHF)患者的潜在益处。然而,临床证据仍然有限。本研究的目的是总结静脉注射尼可地尔治疗ADHF的疗效和安全性。设计:进行系统回顾和荟萃分析。在PubMed、Embase、Cochrane’s Library、Wanfang和CNKI数据库中搜索相关的随机对照试验(RCT)。采用随机效应模型对结果进行组合。结果:8项随机对照试验参与了荟萃分析。汇总结果显示,静脉注射尼可地尔急性治疗可显著改善24岁时的呼吸困难症状 治疗后h,如治疗后呼吸困难的Likert五点量表所示(平均差异[MD]:-0.26,95%置信区间[CI]:-0.40至-0.13,p p p = 0.01)。此外,尼可地尔显著改善了包括左心室射血分数和出院时E/E’在内的超声参数。此外,在长达90的随访期间 天,静脉注射尼可地尔显著降低了主要心血管不良事件的发生率(风险比[RR]:0.55,95%CI:0.32至0.93,p = 治疗相关不良事件的发生率在尼可地尔和对照组之间没有显著差异(RR:1.22,95%CI:0.69~2.15,p = 0.49)。结论:本研究结果表明,静脉注射尼可地尔可能是治疗ADHF患者的有效和安全的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intravenous nicorandil for patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials.

Objectives: Pilot studies have suggested the potential benefits of intravenous nicorandil for patients with acute decompensated heart failure (ADHF). However, clinical evidence remains limited. The aim of the study was to summarize the efficacy and safety of intravenous nicorandil for the treatment of ADHF.

Design: A systematic review and meta-analysis was performed. The search for relevant randomised controlled trials (RCTs) was conducted in PubMed, Embase, Cochrane's Library, Wanfang, and CNKI databases. A random-effects model was employed to combine the results.

Results: Eight RCTs contributed to the meta-analysis. Pooled results showed that acute treatment with intravenous nicorandil could significantly improve the symptom of dyspnea at 24 h after treatment, as evidenced by the five-point Likert scale for dyspnea after treatment (mean difference [MD]: -0.26, 95% confidence interval [CI]: -0.40 to -0.13, p < 0.001). Furthermore, nicorandil significantly reduced serum B natriuretic peptide (MD: -30.03 ng/dl, 95% CI: -47.00 to -13.06, p < 0.001), and N-terminal proBNP (MD: -138.69, 95% CI: -248.06 to -29.31, p = 0.01). In addition, nicorandil significantly improved ultrasonic parameters including left ventricular ejection fraction and E/e' at discharge. Moreover, during the follow-up duration of up to 90 days, intravenous nicorandil significantly reduced the incidence of major adverse cardiovascular events (risk ratio [RR]: 0.55, 95% CI: 0.32 to 0.93, p = 0.03). The incidence of treatment-related adverse events was not significantly different between nicorandil and controls (RR: 1.22, 95% CI: 0.69 to 2.15, p = 0.49).

Conclusions: Results of this study suggest that intravenous nicorandil may be an effective and safe treatment for patients with ADHF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scandinavian Cardiovascular Journal
Scandinavian Cardiovascular Journal 医学-心血管系统
CiteScore
3.40
自引率
0.00%
发文量
56
审稿时长
6-12 weeks
期刊介绍: The principal aim of Scandinavian Cardiovascular Journal is to promote cardiovascular research that crosses the borders between disciplines. The journal is a forum for the entire field of cardiovascular research, basic and clinical including: • Cardiology - Interventional and non-invasive • Cardiovascular epidemiology • Cardiovascular anaesthesia and intensive care • Cardiovascular surgery • Cardiovascular radiology • Clinical physiology • Transplantation of thoracic organs
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信